Development and characterisation of Affimer binders to 4 leading therapeutic antibodies

Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation on assay performance.

Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents. Validation of the Affimer binders’ performance showed: 

• High specificity and reproducible quantification of the therapeutic antibodies within serum
• Batch-to-batch consistency in production.
• Identification and development of the binders within a proven 3 month process.

Download the application note by completing the form.

*By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.